Published in Vaccine Weekly, July 21st, 1997
The protein, cyclophilin A, is known mainly because it binds the immunosuppressive drug cyclosporine. Non-immunosuppressive drugs that bind cyclophilin and inhibit HIV are already under development; the new findings show why they work and provide the basis for improvements.
"These studies suggest new ways of disrupting HIV-1 replication," said Jeremy Luban of Columbia University, New York, in an address to "New Opportunities for HIV Therapy - From Discovery to Clinical Proof-of-Concept," the 2nd Joint Conference of the National Institute of Allergy and Infectious Diseases...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.